PMID: 6160902Dec 15, 1980Paper

Further experience in treating patients with hepatocellular carcinoma in Uganda

Cancer
C L OlwenyS K Kyalwazi

Abstract

One hundred and thirty nine patients with histologically proven hepatocellular carcinoma (HC) were admitted to the Uganda Cancer Institute for treatment. The patients were considerably younger and seemed to have more advanced disease than HC patients in Europe and in North America. Of the 99 evaluable patients, 50 received Adriamycin intravenously; of these, 44% responded, with 10% achieving complete responses. Intraarterial Adriamycin tended to increase the response rate to 75%, but this may be merely a reflection of patient selection. Combination of Adriamycin with other drugs (dichloromethotrexate, 5-azacytidine, Rezoxane and cyclophosphamide) did not enhance its therapeutic effectiveness. The alphafetoprotein response curves observed when Adriamycin was combined with dichloromethotrexate suggested possible antagonisms between the two drugs. Hepatic artery ligation (HAL) is a good and simple palliative procedure with response rates similar to i.v. Adriamycin. However, the administration of Adriamycin after HAL tended to improve on response rates and survival. The toxicities observed were mainly myelosuppression, gastrointestinal disturbance, alopecia, and hyperpigmentation of the skin and mucous membranes.

References

Aug 1, 1977·Cancer·D S Chen, J L Sung
May 13, 1978·Lancet·P J JohnsonI M Murray-Lyon
Jan 1, 1978·Antibiotics and Chemotherapy·C L Olweny
Jan 1, 1973·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·M S Hutt, P P Anthony
May 2, 1974·The New England Journal of Medicine·E T Mays, C S Wheeler

❮ Previous
Next ❯

Citations

Feb 2, 2013·The Indian Journal of Surgery·Anurag ShrimalA V Kulkarni
Jan 1, 1987·Baillière's Clinical Gastroenterology·A Forbes, R Williams
Mar 5, 1998·International Journal of Radiation Oncology, Biology, Physics·W Y LauA K Li
Mar 24, 1983·The New England Journal of Medicine·C E Welch, R A Malt
Dec 19, 1985·The New England Journal of Medicine·R A Malt
Jan 4, 1998·Journal of Gastroenterology and Hepatology·D Y LinY F Liaw
Nov 30, 2004·Expert Opinion on Investigational Drugs·Daniel H PalmerPhilip J Johnson
Dec 1, 1983·International Journal of Radiation Oncology, Biology, Physics·M A Friedman
Feb 9, 2012·British Journal of Haematology·Victoria WalusansaJackson Orem
Mar 1, 1988·Cancer Treatment Reviews·S R NerenstoneM A Friedman
Nov 1, 1988·European Journal of Cancer & Clinical Oncology·S ThongprasertB Sivasomboon
Oct 1, 1982·Journal of Surgical Oncology·P Appelqvist
Jan 1, 1983·Journal of Surgical Oncology·Y T Lee
Jul 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S OkadaK Aoki
Mar 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C L LaiH J Lin
Apr 29, 2006·Oncology·Mohamed HebbarFrançois-René Pruvot
Apr 1, 1992·The Journal of Dermatology·A Konohana
Jun 1, 1988·Alimentary Pharmacology & Therapeutics·A A Dunk, H C Thomas
Apr 21, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Cliff R Davis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.